Cedars-Sinai study revealed that vaccinated cancer patients experienced reduced rates of hospitalization and ICU admission.
RT’s Three Key Takeaways:
- COVID-19 Boosters Reduce Severe Illness in Cancer Patients: Booster vaccinations were associated with a 29% reduction in hospitalizations and ICU admissions among cancer patients, demonstrating strong protection for this vulnerable group.
- Real-World Data Supports Vaccine Recommendations: Analyzing over 161,000 cancer patients across four major U.S. health systems, the study provides the largest evidence to date affirming the effectiveness of mRNA boosters in reducing severe COVID-19 outcomes in cancer care.
- Urgent Need to Increase Booster Uptake: Despite the benefits, booster uptake remains low, with only 38% of cancer patients receiving updated vaccines—highlighting a critical need for stronger patient-provider advocacy and public health outreach.
Vaccine boosters help keep cancer patients from being hospitalized or admitted to intensive care units due to COVID-19, according to a new study led by Cedars-Sinai investigators. Their findings, published in JAMA Oncology, offer real-world evidence to support vaccine recommendations for these patients.
“Cancer patients are a vulnerable population,” said Jane Figueiredo, PhD, director of Community Health and Population Research at Cedars-Sinai and senior author of the study. “Their immune systems can be weakened by their disease and the treatments they receive, which is why major health organizations recommend that these patients be vaccinated against COVID-19. Our study supports these recommendations. We used real-world data across four major health systems in the U.S. to show that these booster vaccines reduce the risk of hospitalization and severe illness.”
Investigators analyzed data on more than 161,000 patients treated for cancer during 2022 and 2023 at Cedars-Sinai, Kaiser Permanente Northern California, Northwell Health, and the Veterans Health Administration.
The data showed COVID-19 boosters reduced cancer patients’ hospitalizations and ICU admissions by 29% and prevented one hospitalization or ICU admission for every 150-166 boosted patients.
“The reduction in hospitalizations was significant, and the number of patients we needed to treat to see a benefit to the boosters is quite low,” said Figueiredo, who is also program leader of Cancer Prevention and Control at Cedars-Sinai. “This shows a great benefit to our cancer patients and should encourage patients to discuss vaccination with their healthcare providers.”
Figueiredo noted that among their sample, the percentage of patients receiving boosters was quite low. By Jan. 1, 2022, 68% had received a booster. And after updated boosters targeting more than one COVID-19 strain had become available, only 38% of patients had received one.
“Whether this is due to patient concerns about safety or provider uncertainty about whether to administer a vaccine during treatment is not clear,” Figueiredo said. “What is clear is that we need to advocate strongly for vulnerable groups, including cancer patients, to receive these vaccines.”
Figueiredo noted that the COVID-19 pandemic was the first opportunity for investigators to examine data on mRNA vaccines, and five years later there is still much to learn about the effectiveness of these vaccines in various populations.
“This is the largest study to date of COVID-19 booster effectiveness in cancer patients, a high-risk population of critical importance,” said Robert Figlin, MD, interim director of Cedars-Sinai Cancer. “It adds substantially to our understanding of the effectiveness of COVID-19 vaccines, and we will undertake additional studies as vaccine formulations change and new variants emerge so that we can make recommendations that best protect the health of our patients.”
Figueiredo’s team is preparing to publish vaccine effectiveness data on patients with autoimmune diseases and patients who have undergone solid organ transplants.
“There are several different groups whose immune systems have been affected in different ways, which gives us an opportunity to expand further our understanding of how these vaccines work,” Figueiredo said.
